{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'in the morning and evening. Subjects should enter the time they take their study treatment', 'in the eDiary.', 'Subjects will be randomly assigned to one of the blinded study treatment regimens in', 'equal proportion (ratio of 1:1:1):', 'UMEC/VI 62.5/25 mcg once daily via ELLIPTA + placebo twice daily via', 'DISKUS', 'UMEC 62.5 mcg once daily via ELLIPTA + placebo twice daily via DISKUS', 'Salmeterol 50 mcg twice daily via DISKUS + placebo once daily via ELLIPTA', 'The randomisation will be stratified based on long-acting bronchodilator usage during', 'the run-in (none, one or 2 long-acting bronchodilators per day).', 'Study treatment/investigational product will be dispensed at Visits 2, 3 and 4.', 'In order to ensure subjects have sufficient doses of study treatment, they must return to', 'clinic within 30 days from V2, 60 and 90 days from V3 and V4 respectively (see Time', 'and event table Section 7.1).', 'Used study drug and rescue medication will be collected at Visits 3, 4 and 5 or at the', 'Early Withdrawal Visit.', '6.4.', 'Planned Dose Adjustments', 'No dose adjustment is allowed for this study', '6.5.', 'Blinding', 'This will be a double-blind double dummy study and the following will apply.', \"The investigator or treating physician may unblind a subject's treatment\", 'assignment only in the case of an emergency OR in the event of a serious', 'medical condition when knowledge of the study treatment is essential for the', 'appropriate clinical management or welfare of the subject as judged by the', 'investigator.', \"Investigators have direct access to the subject's individual study treatment.\", 'It is preferred (but not required) that the investigator first contacts the Medical', 'Monitor or appropriate GSK study personnel to discuss options before unblinding', \"the subject's treatment assignment.\", 'If GSK personnel are not contacted before the unblinding, the investigator must', 'notify GSK as soon as possible after unblinding, but without revealing the', 'treatment assignment of the unblinded subject, unless that information is', 'important for the safety of subjects currently in the study.', 'The date and reason for the unblinding must be fully documented in the eCRF', '36']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', \"A subject will be withdrawn if the subject's treatment code is unblinded by the\", \"investigator or treating physician. GSK's Global Clinical Safety and Pharmacovigilance\", '(GCSP) staff may unblind the treatment assignment for any subject with an SAE. If the', 'SAE requires that an expedited regulatory report be sent to one or more regulatory', \"agencies, a copy of the report, identifying the subject's treatment assignment, may be sent\", 'to investigators in accordance with local regulations and/or GSK policy.', '6.6.', 'Packaging and Labeling', 'The contents of the label will be in accordance with all applicable regulatory', 'requirements.', '6.7.', 'Preparation/Handling/Storage/Accountability', 'No special preparation of the study treatment is required.', 'The investigator or designee must confirm appropriate temperature conditions', 'have been maintained during transit for all study treatment received and any', 'discrepancies are reported and resolved before use of the study treatment.', 'Only subjects enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure environmentally controlled and monitored', '(manual or automated) area in accordance with the labelled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (i.e. receipt, reconciliation and final disposition records).', 'Further guidance and information for final disposition of unused study treatment', 'are provided in the SRM.', 'All ELLIPTA DPI study treatment should be stored up to 25\u00b0C (77\u00b0F). Each All', 'ELLIPTA DPI contains 30 doses and is packaged in a foil pouch with a desiccant', 'sachet and stored in a carton. The inhaler should not be used for more than 30 days', 'after opening the foil. The sites must maintain a daily temperature log for the', 'investigational product.', 'Salmeterol DISKUS should be stored up to 25 \u00b0C.', 'Under normal conditions of handling and administration, study treatment is not', 'expected to pose significant safety risks to site staff. Take adequate precautions to', 'avoid direct eye or skin contact and the generation of aerosols or mists. In the case of', 'unintentional occupational exposure notify the monitor, Medical Monitor and/or GSK', 'study contact.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '37']\n\n###\n\n", "completion": "END"}